Hans L Tillmann

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection
    Josephine H Li
    Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    Hepatology 51:1904-11. 2010
  2. doi Emerging pipeline drugs for hepatitis B infection
    Natravis Cox
    Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Emerg Drugs 16:713-29. 2011
  3. pmc The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
    Hans Ludger Tillmann
    Medizinische Klinik und Poliklinik II, Universitat Leipzig, Germany
    Ther Clin Risk Manag 4:797-802. 2008
  4. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
  5. doi Vitamins? The magic bullet against hepatitis C
    Hans L Tillmann
    Gastroenterology Division, Duke Clinical Research Institute Hepatology Gastroenterology Research, Duke University, Durham, NC 27708, USA
    Expert Rev Anti Infect Ther 10:1273-7. 2012
  6. pmc Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27705, USA
    J Hepatol 55:1195-200. 2011
  7. doi Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment
    H L Tillmann
    Medizinische Hochschule Hannover, Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany
    J Viral Hepat 18:252-61. 2011
  8. doi A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    Gastroenterology 139:1586-92, 1592.e1. 2010
  9. doi Use of thrombopoietic agents for the thrombocytopenia of liver disease
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715 7969, USA
    Semin Hematol 47:266-73. 2010
  10. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010

Detail Information

Publications40

  1. pmc Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection
    Josephine H Li
    Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    Hepatology 51:1904-11. 2010
    ..06), and apolipoprotein E (P = 0.01) were slightly lower in the rs12979860 CC genotype group, whereas levels of high-density lipoprotein cholesterol (P = 0.78) and apolipoprotein C-III (P = 0.74) did not vary by rs12979860 genotype...
  2. doi Emerging pipeline drugs for hepatitis B infection
    Natravis Cox
    Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Emerg Drugs 16:713-29. 2011
    ..The long-term efficacy of combinations of IFN and/or nucleos(t)ide analogs might achieve antiviral synergy, preventing drug resistance and clearing viral covalently close circular DNA and infected cells...
  3. pmc The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
    Hans Ludger Tillmann
    Medizinische Klinik und Poliklinik II, Universitat Leipzig, Germany
    Ther Clin Risk Manag 4:797-802. 2008
    ..The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency...
  4. pmc Metaprotein expression modeling for label-free quantitative proteomics
    Joseph E Lucas
    Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA
    BMC Bioinformatics 13:74. 2012
    ..Additionally, there may be systematic shifts in the sensitivity of the machine between experiments or even through time within the duration of a single experiment...
  5. doi Vitamins? The magic bullet against hepatitis C
    Hans L Tillmann
    Gastroenterology Division, Duke Clinical Research Institute Hepatology Gastroenterology Research, Duke University, Durham, NC 27708, USA
    Expert Rev Anti Infect Ther 10:1273-7. 2012
    ..Vitamin D had repeatedly been reported to be associated with response to HCV therapy. It will be interesting to see whether vitamins such as B12 and D will remain relevant in the light of direct antivirals...
  6. pmc Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27705, USA
    J Hepatol 55:1195-200. 2011
    ..Here we analyzed the association of steatosis with IL28B genotype in treatment naïve patients with CHC...
  7. doi Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment
    H L Tillmann
    Medizinische Hochschule Hannover, Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany
    J Viral Hepat 18:252-61. 2011
    ..This may suggest that HCV either may not be involved in QoL impairment or may induce a process which persists after viral clearance in some patients...
  8. doi A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    Gastroenterology 139:1586-92, 1592.e1. 2010
    ..We analyzed the association between IL28B and the clinical presentation of acute hepatitis C virus (HCV) infection in a homogeneous population...
  9. doi Use of thrombopoietic agents for the thrombocytopenia of liver disease
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715 7969, USA
    Semin Hematol 47:266-73. 2010
    ..A current phase III study is currently evaluating whether this treatment allows successful outcomes and sustained viral eradication...
  10. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
    ..We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients...
  11. pmc Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011
    ..25, 95% confidence interval = 0.08-0.84, P = 0.025) but not with the rate of RBV dose modification (required per protocol at Hb < 9.5 g/dL). There was no association between the ITPA variants and SVR...
  12. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
    ..We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related thrombocytopenia, neutropenia, and leukopenia...
  13. doi Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterology 139:120-9.e18. 2010
    ..We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR...
  14. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
    ..Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined...
  15. doi High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    Hepatology 53:1809-18. 2011
    ..A model averaging approach for identified peptides resulted in an AUROC of 0.86 in the validation cohort, and correctly identified virologic response in 71% of patients without the favorable IL28B "responder" genotype...
  16. doi Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation
    Nazanin Hooman
    Department of Gastroenterology, Medizinische Hochschule Hannover, Hannover, Germany
    Liver Transpl 14:435-42. 2008
    ..That is, IM HBIG is not dose-saving; however, it may be cost-effective if the price per unit is lower. Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dosing schemes...
  17. pmc Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease
    Cynthia A Moylan
    Department of Medicine, Duke University, Durham, NC Department of Medicine, Durham Veterans Affairs Medical Center, Durham, NC
    Hepatology 59:471-82. 2014
    ..Ingenuity Pathway Analysis and IHC confirmed deregulation of metabolic and regenerative pathways in severe NAFLD and revealed overlap among the gene expression patterns of severe NAFLD, cardiovascular disease, and cancer...
  18. ncbi A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels
    Johannes Wiegand
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany
    Antivir Ther 13:547-54. 2008
    ..As quantitative assays for HBsAg recently became available, we have investigated whether quantitative HBsAg measurements can substitute for hepatitis B virus (HBV) DNA quantification in treatment monitoring...
  19. pmc Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C
    Derek D Cyr
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e21854. 2011
    ..To gain further insight into IL28B function we assessed the association of rs12979860 with expression of protein quantitative traits (pQTL analysis) generated using open-platform proteomics in serum from patients...
  20. doi Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients
    Keyur Patel
    Duke Clinical Research Unit and DUMC, Durham, NC, USA
    Antivir Ther 16:1341-6. 2011
    ..Our aims were to prospectively assess the antiviral efficacy and safety of this drug combination in chronic hepatitis C (CHC) patients...
  21. doi Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?
    Hans L Tillmann
    Division of Gastroenterology, GI Hepatology Research Program, Duke Clinical Research Institute, Durham, NC, USA
    Liver Int 32:544-53. 2012
    ..Thus, in the absence of solid evidence based data, the hepatologists could treat their patients with severe acute hepatitis B with lamivudine or the most potent antivirals entecavir or tenofovir...
  22. doi Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues
    Jerzy Jaroszewicz
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Antivir Ther 16:915-24. 2011
    ..Serum interferon-inducible protein-10 (IP-10) has been associated with treatment response in hepatitis C, but data in chronic hepatitis B are lacking. Here, we aimed to investigate potential factors predictive for HBsAg loss...
  23. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010
    ..We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4...
  24. ncbi Differential influence of different hepatitis viruses on quality of life in HIV positive patients
    Hans L Tillmann
    Medizinische Klinik and Poliklinik II, Universitat Leipzig, Philipp Rosenthal Str 27, 04103 Leipzig, Germany
    Eur J Med Res 11:381-5. 2006
    ..HCV has been associated with impaired quality of life in non-HIV infected patients. Little is known concerning the quality of life in HIV-infected individuals in relation to the different viral co-infections. -..
  25. doi Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure
    Johannes Hadem
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Clin Gastroenterol Hepatol 6:339-45. 2008
    ..The accuracy of these parameters in predicting transplantation or death shows significant variation in different countries...
  26. ncbi Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27715 7969, USA
    Curr Gastroenterol Rep 11:5-14. 2009
    ..Phase 3 studies are currently evaluating whether initiating and maintaining antiviral therapy with eltrombopag will lead to an increase in sustained virologic response in chronic hepatitis C infection...
  27. doi HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome
    Benjamin Heidrich
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Liver Int 32:1415-25. 2012
    ..The aim of this study was to investigate the role of HBeAg in patients co-infected with the hepatitis D virus (HDV)...
  28. doi GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients
    Maren Moenkemeyer
    Clinic for Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany
    J Med Virol 80:1933-40. 2008
    ..Untreated HIV-1 patients with GBV-C coinfection have reduced cell surface Fas expression. Lower FMA of T-cells might contribute to prolonged survival of GBV-C coinfected HIV-1 patients...
  29. pmc Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease
    Susan K Murphy
    Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina
    Gastroenterology 145:1076-87. 2013
    ..We investigated whether DNA methylation profiles can distinguish patients with mild disease from those with advanced NAFLD, and how these patterns are functionally related to hepatic gene expression...
  30. ncbi GB virus C infection: is there a clinical relevance for patients infected with the human immunodeficiency virus?
    Thorsten Kaiser
    Medizinische Klinik and Poliklinik II, Universitat Leipzig, Leipzig, Germany
    AIDS Rev 7:3-12. 2005
    ..In this review, we update the current knowledge on GB virus C, its role in HIV infection in the HAART era, and discuss the potential mechanisms of its beneficial effect...
  31. doi Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis
    Thorsten Kaiser
    Medizinische Klinik und Poliklinik II, Universitat Leipzig, Leipzig, Germany
    J Med Virol 80:1195-201. 2008
    ..Reduction of viral load during dialysis session indicates a potential benefit of dialysis in case of HCV associated antiviral therapy...
  32. doi Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver
    Sandra Ciesek
    Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    J Infect Dis 197:355-60. 2008
    ..Thus, these data indicate that a long-term extrahepatic HBV reservoir exists, which is relevant not only for liver transplantation but also for other types of transplantations, including bone marrow grafting...
  33. doi MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection
    Tzu Hao Lee
    Department of Medicine, Duke University Medical Center, Durham, North Carolina
    J Med Virol 87:1722-6. 2015
    ..The mechanism of HCV dyslipidemia is complex and could partly relate to the effect of miR-122 on lipid metabolism which requires further evaluation in a larger study...
  34. doi Therapy of acute and fulminant hepatitis B
    Hans L Tillmann
    Duke Clinical Research Institute, Duke University, Durham, N C, USA
    Intervirology 57:181-8. 2014
    ..Patients in danger of progression towards acute liver failure should be referred to transplant centers as early as possible...
  35. ncbi Longer survival of liver transplant recipients with hepatitis virus coinfections
    Kinan Rifai
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Clin Transplant 21:258-64. 2007
    ..Thus, viral coinfections may be associated with ameliorated courses of diseases under certain conditions...
  36. ncbi Hepatitis C virus infection and the brain
    Hans L Tillmann
    Medizinische Klinik und Poliklinik II, University Leipzig, Philipp Rosenthal Str 27, 04103 Leipzig, Germany
    Metab Brain Dis 19:351-6. 2004
    ..Thus the mechanism for the development of fatigue in HCV infection seems specific for HCV. Delineating the mechanism will be a first step to develop treatment option for this currently untreatable impairment...
  37. doi A rationalized approach to the treatment of patients infected with hepatitis B
    Natravis R Cox
    Division of Gastroenterology and Hepatology, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA
    Mol Diagn Ther 18:203-12. 2014
    ..This article provides an overview of the viral and host genetics of chronic HBV and reviews the clinical utility of serum quantitative hepatitis B surface antigen in the management of patients with chronic HBV infection...
  38. ncbi Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation
    Jens Rosenau
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Liver Transpl 13:367-73. 2007
    ..Further studies should address the question, of whether the use of potent adjuvant systems results in higher response rates...
  39. ncbi Donor origin of de novo hepatocellular carcinoma in hepatic allografts
    Peer Flemming
    Institut fur Pathologie, Medizinische Hochschule Hannover, Hannover, Germany
    Transplantation 76:1625-7. 2003
    ..Because recent data demonstrated a mixed hepatocellular chimerism caused by the integration of host-derived stem cells, a study was conducted on the origin of tumor cells in de novo HCC...
  40. ncbi Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency
    Hans L Tillmann
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Liver Transpl 9:191-6. 2003
    ..Adefovir dipivoxil resulted in significant clinical improvement in this patient with hepatitis B virus-induced fibrosing cholestatic hepatitis, despite the presence of renal impairment and lamivudine resistance...